Formulation Development for Treatment of Tropical Diseases

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".

Deadline for manuscript submissions: closed (1 June 2022) | Viewed by 483

Special Issue Editors

Department of Science and Technology, Universidad Nacional de Quilmes, Bernal B1876, Argentina
Interests: nanomedicines; archaeolipids; archaeosomes; nebulization; antiinflammation; nano-adjuvant; immunostimulant; topical; subcutaneous; TLR-agonist; carotenoids; epigallocatechin; bisphosphonates
Special Issues, Collections and Topics in MDPI journals
Department of Biology, York Biomedical Research Institute, University of York, York YO10 5DD, UK
Interests: parasitic diseases; drug discovery; leishmaniasis; drug development; skin drug delivery
Department of Infection Biology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
Interests: PK-PD relationship; topical formulation; predictive models for drugs and vaccines and leishmaniasis control

Special Issue Information

Dear Colleagues,

Many tropical diseases, a term that includes both diseases of poverty, like malaria, and the neglected tropical diseases (NTDs), like leishmaniasis, Chagas disease, and mycetoma, are in urgent need of new treatments.
 
Formulation development, aimed at optimizing drug exposure at the biophase, has been a central part of the search for new treatments with varying levels of success. Nanotechnologies masking suboptimal API properties, for example, liposomes, have been the key to treatment advances for visceral leishmaniasis (kala-azar) and also the subject of research with a wide variety of nanoparticles. Another form of this disease, cutaneous leishmaniasis, has focused research on topical formulations. The multi-drug treatments for malaria and tuberculosis, with the demands for patient compliance and adherence, have ensured that co-formulations of fixed-dose combinations are to the fore. Long-acting depot formulations are less common but discussed for Chagas disease as well as malaria prophylaxis. The demand for pediatric formulations is common to all infectious diseases and has been another focus of research, for schistosomiasis, Chagas disease, and malaria. While some of these formulations are promising, translational feasibility is often hindered by cost stability and scaling-up complications.
 
This Special Issue presents articles describing the performance of novel antimicrobial, antiprotozoal, and anthelmintic formulations and nanomedicines administered by both systemic and local (topical, mucosal, or inhalation) routes, to optimize delivery and efficacy while ensuring minimal side effects.

Prof. Dr. Eder Lilia Romero
Dr. Katrien Van Bocxlaer
Prof. Dr. Simon Croft
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop